Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI109253

Aldosterone Stimulation of Riboflavin Incorporation into Rat Renal Flavin Coenzymes and the Effect of Inhibition by Riboflavin Analogues on Sodium Reabsorption

Daniel Trachewsky

Department of Medicine, Oklahoma University College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190

Department of Biochemistry, Oklahoma University College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190

Department of Molecular Biology, Oklahoma University College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190

Find articles by Trachewsky, D. in: PubMed | Google Scholar

Published December 1, 1978 - More info

Published in Volume 62, Issue 6 on December 1, 1978
J Clin Invest. 1978;62(6):1325–1333. https://doi.org/10.1172/JCI109253.
© 1978 The American Society for Clinical Investigation
Published December 1, 1978 - Version history
View PDF
Abstract

This study was designed to investigate a possible relationship between the effect of aldosterone upon urinary electrolytes and the incorporation of [14C]riboflavin into renal [14C]flavin mononucleotide (FMN) and [14C]flavin adenine dinucleotide (FAD). Adrenalectomized Sprague-Dawley rats that weighed between 185 and 210 g were pretreated with 15 μg/100 g body wt dexamethasone intraperitoneally. 16 h later they were administered aldosterone (1.5 μg/100 g body wt) and [14C]riboflavin (5.0 μCi/200 g body wt). The urethra of each rat was ligated, and the rats were sacrificed by decapitation 3 h later. The urine was aspirated from the bladders of each rat and analyzed for total Na+ and K+ excretion while the kidneys were removed and the formation of [14C]FMN and [14C]FAD was determined for each kidney. There was a significant increase in the formation of renal [14C]FMN and [14C]FAD (27.3 and 14.4%, respectively) after aldosterone treatment. Aldosterone significantly decreased the excretion of Na+ by 50%, and increased that of K+ by 55%.

To determine if the increased incorporation of [14C]riboflavin into renal [14C]FMN and [14C]FAD was an important intermediary step in the aldosterone-induced alterations in urinary Na+ and K+, the riboflavin analogues 7,8-dimethyl-10-formylmethyl isoalloxazine or 7,8-dimethyl-10-(2′-hydroxyethyl) isoalloxazine were given to the animals i.p. to diminish the conversion of riboflavin to FMN by competitively inhibiting the enzyme flavokinase (EC 2.7.1.26). These analogues were found to significantly counteract the decreased urinary excretion of Na+ as a result of aldosterone from 26±9% to 124±58% (SEM) with a dose-related response when administered from 10 to 25 μg/100 g body wt. The same doses of the analogues that significantly increased the urinary output of Na+ when administered simultaneously with aldosterone also significantly decreased the formation of renal [14C]FMN from 15±4 to 38±3% when compared with the effects of aldosterone alone. The analogues exerted no significant effect on the increased urinary excretion of K+ by aldosterone. The analogues alone had no influence on urinary Na+ and K+ output or the formation of renal [14C]FMN and [14C]FAD at the dose levels that we investigated.

These data strongly suggest that the enhanced synthesis of renal FMN and FAD may be a causative factor in the increased reabsorption of Na+ as a result of aldosterone; and, consequently, riboflavin analogues may function as a novel class of antimineralocorticoids.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1325
page 1325
icon of scanned page 1326
page 1326
icon of scanned page 1327
page 1327
icon of scanned page 1328
page 1328
icon of scanned page 1329
page 1329
icon of scanned page 1330
page 1330
icon of scanned page 1331
page 1331
icon of scanned page 1332
page 1332
icon of scanned page 1333
page 1333
Version history
  • Version 1 (December 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts